



IN THE UNITED STATES PATENT OFFICE

RECEIVED
NOV 01 2002
TECH CENTER 1600/2900

Application Ser No. 10/083,529
Inventor: U.N.Das
Title: A method of stabilizing and potentiating.....

Atty docket No. UND 99.02 D1
Group Art Unit 1616
Examiner: Alton Pryor

Box: Non-Fee Amendment
Assistant Commissioner of Patents
Washington DC 20231

RESPONSIVE AMENDMENT

Responsive to the Official Letter mailed on 08/06/2002, please find enclosed revised claim pages numbered 51 to 55, containing revised claims 2, 3, 4, and 6, and un-revised claims 1, 5, and 7. Also enclosed is a clean copy of all the claims 1-7 as required.

Remarks

The claims have been amended with a view to overcoming the Examiner's 35 USC 112 rejection and with a view to advancing the prosecution to completion.

In particular, the term "derivative" at line 3 of claim 3 is deleted and replaced by "mixture". The term "mixture" is amply supported by the specification as originally filed, as exemplified by the use of the term "mixture" at least in line 39 of text page 30, and line 36 of text page 31. It is submitted that the term "mixture" now used in claim 3 does not introduce any new matter.

Claim 2 has been amended to replace the term "including" by "comprising", as suggested by the Examiner.

Claims 4 and 6 have been revised to delete the terms "Angiostatin and Endostatin" and insert the expression "anti-angiogenic substance/s", which as per the text originally filed, are a naturally occurring protein. Support for the term "anti-angiogenic substances" is present in the text as originally filed, at least at line 25 of page 18. More particularly, in amended claims 4 and 6, the replacement term "anti-angiogenic substance naturally occurring as a protein" is used to replace the terms "Angiostatin" and "Endostatin". It is submitted that the replacement term is consonant with the text as originally filed. It is noted that the naturally occurring protein is obtainable from plasminogen as stated at lines 14 and 35 on text page 8 as originally filed. It is further submitted that the amended claims 4 and 6, as also the other claims, do not introduce any new matter, or obscurity, or lack of support.